摘要
目的探讨柳氮磺胺吡啶联合通督温阳灸法在治疗强直性脊柱炎的临床效果。方法选取强直性脊柱炎患者120例,收治时间为2015年1月~2016年6月,采用随机数字表法将患者随机分成三组,每组40例。A组采用口服柳氮磺胺吡啶治疗,B组采用通督温阳灸法治疗,C组采用柳氮磺胺吡啶联合通督温阳灸法治疗。治疗4个月后,评价三组患者的疗效,比较三组患者治疗前后在BASFI和BASDAI评分、临床表征以及血沉(ESR)和C反应蛋白(CRP)含量上的变化。结果治疗4个月后,A组的总有效率为77.5%,B组为70%,C组为95%,C组的临床疗效均优于A、B组,且差异均有统计学意义(P<0.05)。三组患者的各项临床指标较治疗前均有一定程度的改善(P<0.05),C组在BASFI和BASDAI评分、枕墙距、指地距、胸廓活动度以及ESR、CRP含量上的变化均优于A、B组(P<0.05);尤其在VAS评分和晨僵时间这两方面上显著优于A、B组,且差异均有统计学意义(P<0.01)。结论柳氮磺胺吡啶联合通督温阳灸法治疗强直性脊柱炎效果更佳,其可有效改善患者的临床症状,提高治疗效果。
Objective To investigate the clinical effect of tongduwenyang moxibustion combined with sulfasalazine in the treatment of ankylosing spondylitis.Methods Selected160cases of patients with AS in our hospital from January2015to June2016,all the patients were divided into three groups according to the serial number in the envelope,each group consisted of40patients.Group A were treated with tongduwenyang moxibustion;Group B were treated with oral sulfasalazine;Group C used tongduwenyang moxibustion combined with sulfasalazine in treatment.After4months of treatment,the efficacy ofthe three groups was evaluated,the changes of BASFI and BASDAI scores,clinical manifestations,and the contents of ESR and CRP were compared beforeand after treatment.Results The total effective rate in group A was70%,77.5%in group B and95%in group C,The clinical curative effect of group C wasbetter than that of group A,B group,and the difference was statistically significant(P<0.05).After4months,the indexes of the three groups were improvedto some extent(P<0.05),group C in the BASFI and BASDAI score,pillow wall distance,mean distance,thoracic activity,ESR and CRP content were better than group A and B(P<0.05),especially the VAS score and morning stiffness were better than group A and B,and the difference was statistically significant(P<0.01).Conclusion Tongduwenyang moxibustion combined with sulfasalazine has better effect in the treatment of ankylosing spondylitis,and it can effectively improve the clinical symptoms of the patients and improve the therapeutic effect,worthy of further clinical application.
作者
何洲
梁鼎天
张圳锋
HE Zhou;LIANG Ding-tian;ZHANG Zhenfeng(The hospital of Guangdong industry university, Guangzhou 510090, China)
出处
《中国处方药》
2017年第3期1-3,共3页
Journal of China Prescription Drug
基金
2016年广东省中医药常规科研项目立项资助课题(20161219)